Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
DDX11 CRISPR/Cas9 KO Plasmid (h): sc-418103
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- DDX11 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the DDX11 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: DDX11 Antibody (D-2): sc-271711
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DDX11 CRISPR/Cas9 KO Plasmid (h) | sc-418103 | 20 µg | $397.00 |
Overview
DDX11 (DEAD/H-box helicase 11), also known as ChlR1, is a DNA helicase that supports genome stability by promoting sister chromatid cohesion and efficient DNA replication. It participates in replication-coupled DNA repair and fork progression, intersecting with cohesion establishment and broader DNA damage response pathways. DDX11 activity helps prevent replication stress–associated chromosomal breakage and aneuploidy, linking its function to mechanisms that safeguard chromosome segregation. Genetic disruption or dysfunction of DDX11 is associated with cohesin-related genome instability phenotypes, including Warsaw breakage syndrome, making it relevant for studying cohesion defects and replication-associated DNA damage.
DDX11 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the DDX11 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the DDX11 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the DDX11 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish DDX11 protein expression.
This CRISPR knockout system enables efficient generation of DDX11-deficient cell models for investigation of DDX11 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting DDX11 exon(s) critical for DDX11 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple DDX11 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by DDX11 CRISPR/Cas9 KO Plasmid (h) and DDX11 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the DDX11 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by DDX11 HDR Plasmid (h) and DDX11 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by DDX11 homology arms to support homology-directed repair at defined DDX11 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.